Artivion Reports $125.8 Million Revenue in Q2 2026, Net Loss of $13.5 Million

Artivion, Inc. reported a total revenue of $125.8 million for the second quarter of 2026, marking an 11% increase from $113.0 million in the same period of 2025. The growth was driven by a rise in sales across all product lines, particularly aortic stent grafts and On-X products, which saw increases of 16% and 19%, respectively. For the first half of 2026, total revenues reached $242.1 million, up 14% from $212.0 million in the prior year. However, the company recorded a net loss of $13.5 million for the quarter, compared to a net income of $1.3 million in the same quarter last year, resulting in a loss per share of $0.28.

The financial performance reflects significant changes compared to the previous fiscal period, particularly in operating expenses, which surged by 37% to $88.9 million for the second quarter, largely due to acquisition-related costs and increased investments in sales and marketing. The gross margin for the quarter was $80.5 million, representing a 10% increase from the previous year, although the gross margin percentage slightly decreased to 64% from 65% due to unfavorable product costs and geographic mix.

Strategically, Artivion completed the acquisition of Endospan in May 2026 for approximately $178.1 million, which is expected to enhance its aortic arch product portfolio. The acquisition has already led to increased operational costs, including $11.7 million in transaction-related expenses. Additionally, the company has been actively involved in the commercialization of PerClot, a hemostatic agent, which contributed $1.9 million in revenue during the second quarter.

Operationally, Artivion's customer base and product adoption rates have shown positive trends. The company reported a significant increase in the volume of aortic stent grafts sold, particularly in North America and EMEA regions. The total cash and cash equivalents as of June 30, 2026, stood at $77.3 million, alongside $30 million in unused commitments under a revolving credit facility, indicating a solid liquidity position to support ongoing operations and strategic initiatives.

Looking ahead, Artivion anticipates continued revenue growth driven by its expanding product portfolio and market presence. The company is focused on enhancing its operational efficiencies and leveraging its recent acquisitions to capture a larger market share in the medical device sector. However, management has acknowledged potential risks related to market conditions, regulatory approvals, and foreign currency fluctuations that could impact future performance.